
Auris Medical (NASDAQ: EARS) has announced that it has initiated enrolment for a new Phase III trial that will evaluate …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

